Gilead Sciences Prices Hepatitis C Drug at $84,000; Versartis Commences Trading on the NASDAQ

Follow this company

Companies Mentioned

03/24/2014 [ACCESSWIRE]

Oracle Corporation (NYSE: ORCL) – For an in-depth report on Oracle Corporation follow:

ORCL closed down 2.27% on Friday with nearly 34 million shares traded. The stock was one of the most active stocks on the NYSE and came a dollar short of its 52-week high during intra-day trading. During Oracle’s conference call to announce its fiscal Q3 2014 earnings, Oracle mentioned that its Data Analytics division saw very strong growth of 40% during the quarter.

Gilead Sciences Inc. (NASDAQ: GILD) - For an in-depth report on Gilead Sciences Inc. follow:

Shares of Gilead Sciences closed down 4.57% on nearly 37 million shares traded. The stock was one of the most active stocks on the NASDAQ. U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers.

Advanced Cannabis Solutions, Inc. (OTCBB: CANN) - For an in-depth report on Advanced Cannabis Solutions, Inc. follow:

CANN closed down 17.12% on Friday and was one of the biggest decliners in the OTCBB marketplace. There was no significant news to explain the fall. Advanced Cannabis Solutions is a provider of services to the regulated cannabis industry throughout the United States and leases growing space and related facilities (commercial real estate and equipment) to licensed marijuana business operators for their production needs.

Versartis, Inc. (NASDAQ: VSAR) - For an in-depth report on Versartis, Inc. follow:

Shares of VSAR closed up 49.38% on Friday with a little over 6 million shares traded. The stock hit a high of 52-week high of $36.30 during intra-day trading after the stock commenced on The NASDAQ Stock Market that day. Versartis is an innovative company dedicated to improving the treatment of growth hormone deficiency.


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name